Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2021 | $11.00 | Neutral → Buy | Citigroup |
| 9/28/2021 | Neutral → Buy | Citigroup | |
| 8/6/2021 | $13.00 → $6.00 | Sector Perform | RBC Capital |
| 8/6/2021 | $9.00 → $8.00 | Sell | Goldman Sachs |
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma's first commercial product. Product revenue, net in the third quarter of 2024 was $56.1 million, compared to $51.6 million in the third quarter of 2023. Product revenue, net in the first nine months of 2024 was $140.8 million, compared to $149.9 million in the first nine months of 2023. Based on accounting principles generally accepted in the United States (GA
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, November 7, 2024, following the release of its third quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after complet
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2024. Unless otherwise stated, all comparisons are for the second quarter 2024 compared to the second quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the second quarter of 2024 was $44.4 million, compared to product revenue, net of $51.6 million in the second quarter of 2023. Product revenue, net in the first six months of 2024 was $84.6 million, compared to $98.3 million in the first six months of 2023. Based on accounting principles generally accepted in th
SC 13G - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
10-Q - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in combination with endocrine therapy for the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) recurrent or metastatic breast cancer who have been previously treated with CDK 4/6 inhibitors and received at least two prior lines of endocrine therapy in the recurrent or metastatic setting. The ALISCA™-Breast1 trial will enroll up to 150 patients who will be randomized (1:1:1) to receive alisertib dosed at either 30 mg, 40 mg
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma's first commercial product. Product revenue, net in the third quarter of 2024 was $56.1 million, compared to $51.6 million in the third quarter of 2023. Product revenue, net in the first nine months of 2024 was $140.8 million, compared to $149.9 million in the first nine months of 2023. Based on accounting principles generally accepted in the United States (GA
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on November 4, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 5,625 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, November 1, 2
Citigroup upgraded Puma Biotech. from Neutral to Buy and set a new price target of $11.00
Citigroup upgraded Puma Biotechnology from Neutral to Buy
RBC Capital reiterated coverage of Puma Biotechnology with a rating of Sector Perform and set a new price target of $6.00 from $13.00 previously
Ratings for Puma Biotechnology (NASDAQ:PBYI) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. This current average has not changed from
HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $7 price target.
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor
Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)